Stock listing
BX Swiss:RPRX Royalty Pharma plc Aktie
Swiss listing (BX Swiss) of Royalty Pharma plc · home listing NASDAQ:RPRX
Follow Royalty Pharma plc into a list and get an email when it puts out news.
Home listing price · NASDAQ:RPRX
$68.45 USD -0.22 (-0.3%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RPRX
- Day range
- $67.95 – $68.83 USDNov 20, 2026
- Volume
- 3.53M sharesNov 20, 2026
- Market cap
- $30.48B USDAt the close on Nov 20, 2026 · price × 445.3M shares outstanding
- 52-week range
- $37.31 – $70.37 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $198.5M USDMedian day 2.89M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RPRX · Home | $68.45 USD | -0.22 (-0.3%) | 3,531,035 | $68.17 | $68.83 | $67.95 | $68.67 | Close on Nov 20, 2026 |
| Frankfurt:RPD | €61.01 EUR | +0.28 (+0.5%) | — | €61.01 | €61.01 | €61.01 | €60.73 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RPRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $68.45 | -0.22 | -0.3% | $68.17 | $68.83 | $67.95 | 3,531,035 | |
| $68.67 | -0.01 | 0.0% | $68.73 | $69.57 | $68.32 | 3,192,451 | |
| $68.68 | +0.155 | +0.2% | $67.92 | $68.77 | $67.62 | 2,622,511 | |
| $68.53 | -0.785 | -1.1% | $70.00 | $70.00 | $68.34 | 2,998,938 | |
| $69.31 | +0.34 | +0.5% | $68.77 | $69.43 | $68.14 | 2,951,218 | |
| $68.97 | -1.04 | -1.5% | $70.34 | $70.37 | $68.75 | 3,784,342 | |
| $70.01 | +0.56 | +0.8% | $69.04 | $70.27 | $68.88 | 3,532,759 | |
| $69.45 | +0.68 | +1.0% | $68.26 | $69.59 | $67.73 | 3,421,218 | |
| $68.77 | +1.47 | +2.2% | $67.50 | $69.04 | $66.96 | 3,675,372 | |
| $67.30 | -0.27 | -0.4% | $66.52 | $68.15 | $66.52 | 4,812,984 | |
| $67.57 | +0.01 | 0.0% | $68.00 | $69.77 | $67.51 | 4,896,632 | |
| $67.56 | +1.16 | +1.7% | $65.65 | $67.66 | $64.84 | 3,795,482 | |
| $66.40 | -0.12 | -0.2% | $66.57 | $67.44 | $66.12 | 3,149,198 | |
| $66.52 | -0.66 | -1.0% | $66.97 | $67.10 | $66.43 | 2,870,933 | |
| $67.18 | +1.25 | +1.9% | $67.00 | $67.71 | $66.40 | 4,660,607 | |
| $65.93 | +1.11 | +1.7% | $65.34 | $66.29 | $64.93 | 2,450,400 | |
| $64.82 | -0.46 | -0.7% | $64.82 | $65.34 | $63.49 | 2,414,400 | |
| $65.28 | +0.52 | +0.8% | $64.71 | $65.51 | $64.45 | 2,701,900 | |
| $64.76 | +0.90 | +1.4% | $64.14 | $65.35 | $64.06 | 4,108,100 | |
| $63.86 | +0.11 | +0.2% | $63.50 | $63.97 | $63.01 | 4,015,500 | |
| $63.75 | +1.60 | +2.6% | $62.34 | $63.84 | $62.34 | 2,808,500 | |
| $62.15 | -0.10 | -0.2% | $62.10 | $62.90 | $62.00 | 2,742,100 | |
| $62.25 | +1.98 | +3.3% | $60.92 | $62.42 | $60.78 | 2,493,000 | |
| $60.27 | -0.69 | -1.1% | $60.54 | $61.12 | $60.04 | 2,813,200 | |
| $60.96 | +1.34 | +2.2% | $59.89 | $61.31 | $59.72 | 5,786,400 | |
| $59.62 | +0.63 | +1.1% | $59.75 | $60.41 | $59.50 | 3,407,000 | |
| $58.99 | +2.42 | +4.3% | $56.93 | $59.08 | $56.78 | 2,828,100 | |
| $56.57 | -1.21 | -2.1% | $57.70 | $57.97 | $56.42 | 3,582,400 | |
| $57.78 | +0.85 | +1.5% | $57.04 | $57.92 | $56.85 | 2,465,300 | |
| $56.93 | +0.72 | +1.3% | $56.03 | $57.08 | $55.72 | 2,882,000 | |
| $56.21 | -0.55 | -1.0% | $56.57 | $56.71 | $55.13 | 2,847,200 | |
| $56.76 | +0.32 | +0.6% | $56.61 | $57.16 | $56.41 | 3,671,200 | |
| $56.44 | -0.22 | -0.4% | $56.66 | $57.13 | $56.04 | 2,434,100 | |
| $56.66 | -0.50 | -0.9% | $57.10 | $57.25 | $56.01 | 3,958,000 | |
| $57.16 | -0.47 | -0.8% | $57.64 | $57.91 | $56.96 | 2,229,500 | |
| $57.63 | -0.73 | -1.3% | $58.36 | $58.40 | $57.22 | 3,245,200 | |
| $58.36 | +0.14 | +0.2% | $58.07 | $58.64 | $57.70 | 3,653,700 | |
| $58.22 | -0.15 | -0.3% | $58.19 | $58.48 | $57.51 | 2,885,200 | |
| $58.37 | +0.16 | +0.3% | $57.88 | $58.77 | $57.63 | 1,862,600 | |
| $58.21 | -0.08 | -0.1% | $58.50 | $58.50 | $57.68 | 1,869,500 | |
| $58.29 | +0.64 | +1.1% | $57.69 | $58.87 | $57.66 | 2,019,000 | |
| $57.65 | -0.87 | -1.5% | $58.52 | $59.02 | $57.63 | 2,804,300 | |
| $58.52 | +0.08 | +0.1% | $58.27 | $59.03 | $57.86 | 2,691,400 | |
| $58.44 | +0.03 | +0.1% | $58.56 | $59.07 | $57.82 | 3,231,900 | |
| $58.41 | -0.52 | -0.9% | $58.63 | $58.96 | $57.97 | 7,101,500 | |
| $58.93 | +0.46 | +0.8% | $58.81 | $59.18 | $58.46 | 2,062,500 | |
| $58.47 | 0.00 | 0.0% | $59.00 | $59.17 | $58.27 | 2,157,600 | |
| $58.47 | -0.58 | -1.0% | $59.00 | $59.20 | $57.91 | 2,749,600 | |
| $59.05 | +0.44 | +0.8% | $58.66 | $59.55 | $57.75 | 2,967,200 | |
| $58.61 | -0.14 | -0.2% | $58.95 | $59.54 | $58.35 | 2,595,900 | |
| $58.75 | -1.84 | -3.0% | $60.45 | $60.71 | $58.64 | 3,324,500 | |
| $60.59 | 0.00 | 0.0% | $60.60 | $60.80 | $59.31 | 4,344,500 | |
| $60.59 | -3.37 | -5.3% | $59.21 | $60.86 | $58.63 | 8,631,500 | |
| $63.96 | +0.08 | +0.1% | $63.55 | $64.38 | $63.43 | 3,401,300 | |
| $63.88 | +0.77 | +1.2% | $63.57 | $63.94 | $62.50 | 2,761,500 | |
| $63.11 | +0.79 | +1.3% | $62.66 | $63.29 | $62.03 | 3,142,800 | |
| $62.32 | +0.91 | +1.5% | $61.82 | $62.58 | $61.61 | 2,629,300 | |
| $61.41 | +0.56 | +0.9% | $60.81 | $61.68 | $60.39 | 3,894,500 | |
| $60.85 | -1.07 | -1.7% | $61.92 | $62.01 | $60.66 | 1,701,100 | |
| $61.92 | +0.12 | +0.2% | $61.42 | $62.35 | $61.01 | 2,093,700 | |
| $61.80 | -0.27 | -0.4% | $62.04 | $62.28 | $61.49 | 1,478,100 | |
| $62.07 | +0.74 | +1.2% | $61.33 | $62.46 | $60.87 | 1,705,153 | |
| $61.33 | +0.02 | 0.0% | $61.19 | $61.54 | $60.80 | 2,357,873 | |
| $61.31 | +0.73 | +1.2% | $60.53 | $61.60 | $60.37 | 2,325,100 | |
| $60.58 | -1.15 | -1.9% | $61.33 | $62.13 | $60.37 | 3,143,000 |
- Ticker
- BX Swiss:RPRX
- Asset type
- Stock
- Exchange
- BX Swiss
- Currency
- CHF
What changed lately
Latest news release · Nov 12, 2026
Royalty Pharma to present at the UBS Global Biopharma Conference
Latest earnings call · Nov 4, 2026
Royalty Pharma (NASDAQ:RPRX) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 4, 2026
Q3 2026 Earnings Presentation
Earnings · 30 slides
Latest news
Royalty Pharma to present at the UBS Global Biopharma Conference
Nov 12, 2026
Closed $69.31 (+0.5%) on Nov 13, 2026
Royalty Pharma reports third quarter 2026 results
Nov 4, 2026
Closed $67.56 (+1.7%) on Nov 4, 2026
Royalty Pharma declares fourth quarter 2026 dividend
Oct 16, 2026
Closed $60.96 (+2.2%) on Oct 16, 2026
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
Oct 9, 2026
Closed $56.93 (+1.3%) on Oct 9, 2026
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
Sep 15, 2026
Closed $58.47 (0.0%) on Sep 16, 2026
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
Sep 4, 2026
Closed $60.59 (-5.3%) on Sep 8, 2026
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
Aug 12, 2026
Closed $58.56 (-1.1%) on Aug 13, 2026
Royalty Pharma reports second quarter 2026 results
Aug 5, 2026
Closed $57.75 (+0.5%) on Aug 5, 2026
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
Aug 3, 2026
Closed $57.17 (-2.2%) on Aug 3, 2026
Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune
Jul 23, 2026
Closed $59.02 (+0.5%) on Jul 23, 2026
Royalty Pharma plc on 6ix
- News releases
- 38 in the last 12 months · 198 in all · newest Nov 12, 2026 · oldest 2020
- Calls
- 24 calls with a replay · 24 with a transcript · latest Nov 4, 2026
- Decks
- 68 decks · latest Nov 4, 2026
Where Royalty Pharma plc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RPRX · Home listing | NASDAQ | United States | USD |
| gettex:RPD | gettex | Germany | EUR |
| LS Exchange:A2P62D | LS Exchange | Germany | EUR |
| Tradegate:RPD | Tradegate | Germany | EUR |
| Lang & Schwarz:A2P62D | Lang & Schwarz | Germany | EUR |
| Frankfurt:RPD | Frankfurt | Germany | EUR |
| BMV:RPRXN | BMV | Mexico | MXN |
| BX Swiss:RPRX · This page | BX Swiss | Switzerland | CHF |
| BIVA:RPRXN | BIVA | Mexico | MXN |
| BOATS:RPRX | BOATS | United States | USD |
| Dusseldorf:RPD | Dusseldorf | Germany | EUR |
| Munich:RPD | Munich | Germany | EUR |
| Stuttgart:RPD | Stuttgart | Germany | EUR |
| Hamburg:RPD | Hamburg | Germany | EUR |
| Hanover:RPD | Hanover | Germany | EUR |
| Xetra:RPD | Xetra | Germany | EUR |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $38.52B USD
- P/E
- 45.3×
- EV/sales
- 14.7×
- EV/EBITDA
- 25.7×
- Price/book
- 3.1×
- Gross margin
- 87.3%
- Operating margin
- 57.1%
- Net margin
- 25.7%
- Debt to equity
- 0.9×
- Beta vs S&P 500
- 0.22
Forecasts
5 strong buy · 2 buy · 2 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 72.00 USD · Analysts' mean
- EPS, year to Dec 2026
- 5.39 · 6 analysts
- Revenue, year to Dec 2026
- 3.52B · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Pablo Legorreta | Founder & Chief Executive Officer |
| Terrance Coyne | Chief Financial Officer |
| Arthur McGivern | General Counsel & Investments |
| Nick Montemarano | Executive Director, Investor Relations |
| Eric Schneider | Chief Technology Officer |
| Greg Raskin | Head of Academic Initiatives |
| Jim Reddoch | Chief Scientific Officer & Investments |
| Kenneth Sun | Head of Asia |
| Lucas Glass | Head of Artificial Intelligence |
| Marshall Urist | Head of Research & Investments |
| Scott Raichilson | Chief Accounting Officer |
Board
| Director | Role |
|---|---|
| Bonnie Bassler | Board Member |
| Carole Ho | Board Member |
| Cathy Engelbert | Board Member |
| David C. Hodgson | Vice Chairman |
| Elizabeth Weatherman | Board Member |
| Greg Norden | Board Member |
| Nick Montemarano | Executive Director, Investor Relations |
| Pablo Legorreta | Founder & Chief Executive Officer |
| Ted W. Love | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Royalty Pharma (NASDAQ:RPRX) Q3 2026 Earnings Call | Wed, Nov 04, 2026 · 8:00 AM ET | Replay |
| Royalty Pharma (NASDAQ:RPRX) Q2 2026 Earnings Call | Wed, Aug 05, 2026 · 8:00 AM ET | Replay |
| Royalty Pharma (NASDAQ:RPRX) Q1 2026 Earnings Call | Wed, May 06, 2026 · 8:00 AM ET | Replay |
| Royalty Pharma (NASDAQ:RPRX) Q4 2025 Earnings Call | Wed, Feb 11, 2026 · 8:00 AM ET | Replay |
| Royalty Pharma (NASDAQ:RPRX) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 8:00 AM ET | Replay |
| Royalty Pharma (NASDAQ:RPRX) Q2 2025 Earnings Call | Wed, Aug 06, 2025 · 8:00 AM ET | Replay |
| Royalty Pharma (NASDAQ:RPRX) Q1 2025 Earnings Call | Thu, May 08, 2025 · 8:30 AM ET | Replay |
| Royalty Pharma (NASDAQ:RPRX) Q4 2024 Earnings Call | Tue, Feb 11, 2025 · 8:30 AM ET | Replay |
| Royalty Pharma (NASDAQ:RPRX) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 8:30 AM ET | Replay |
| Royalty Pharma (NASDAQ:RPRX) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 8:00 PM ET | Replay |
All 24 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · Before open | +1.8% |
| Q2 2026 | Aug 5, 2026 · Before open | +0.5% |
| Q1 2026 | May 6, 2026 · Before open | +0.6% |
| Q4 2025 | Feb 11, 2026 · Before open | +0.1% |
| Q3 2025 | Nov 5, 2025 · Before open | +6.8% |
| Q2 2025 | Aug 6, 2025 · Before open | −2.1% |
| Q1 2025 | May 8, 2025 · Before open | +1.1% |
| Q4 2024 | Feb 11, 2025 · Before open | +1.7% |
| Q3 2024 | Nov 6, 2024 · Before open | −3.3% |
| Q2 2024 | Aug 8, 2024 · Before open | −4.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | −0.1% |
| Q4 2023 | Feb 15, 2024 · Before open | +2.5% |
| Q3 2023 | Nov 8, 2023 · Before open | +0.3% |
| Q2 2023 | Aug 8, 2023 · Before open | −0.9% |
| Q1 2023 | May 9, 2023 · Before open | −4.3% |
| Q4 2022 | Feb 15, 2023 · Before open | −0.8% |
| Q3 2022 | Nov 8, 2022 · Before open | +0.8% |
| Q2 2022 | Aug 4, 2022 · Before open | −0.8% |
| Q1 2022 | May 5, 2022 · Before open | −5.6% |
| Q4 2021 | Feb 15, 2022 · Before open | +3.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 30 slides | Nov 4, 2026 |
| Investor Presentation (November 2026) | Investor deck | 91 slides | November 2026 |
| Merger or Acquisition (November 2026) | Merger or acquisition | 5 slides | November 2026 |
| Q2 2026 Earnings Presentation | Earnings | 33 slides | Aug 5, 2026 |
| Investor Presentation (August 2026) | Investor deck | 90 slides | August 2026 |
| Investor Presentation (August 2026) | Investor deck | 91 slides | August 2026 |
| Merger or Acquisition (August 2026) | Merger or acquisition | 7 slides | August 2026 |
| Investor Presentation (July 2026) | Investor deck | 7 slides | July 2026 |
| Q1 2026 Earnings Presentation | Earnings | 37 slides | May 6, 2026 |
| Investor Presentation (May 2026) | Investor deck | 90 slides | May 2026 |
Show 50 decks
This page holds 50 of 68 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Senior unsecured notes Announced: US$2B · BofA Securities +15 Dealers: BofA Securities (co-lead), Goldman Sachs & Co. LLC (co-lead), J.P. Morgan (co-lead), Morgan Stanley (co-lead), TD Securities (co-lead), Citigroup, DNB Carnegie, SMBC Nikko, SOCIETE GENERALE, US Bancorp, Academy Securities, AmeriVet Securities, Blaylock Van, LLC, Cabrera Capital Markets LLC, Drexel Hamilton, R. Seelaus & Co., LLC Use of proceeds: General corporate purposes | Sep 2, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$28.00 a share on Jun 15, 2020.
- Price
- US$28.00 a share
- Shares offered
- 77,681,670 Class A ordinary shares · 60,000,000 from the company and 17,681,670 from selling shareholders
- Offering size
- US$2.18 billion
- Underwriters' option
- Up to 11,652,250 more shares
- Underwriters
- J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs & Co. LLC, Citigroup, UBS Investment Bank, Evercore ISI, Cowen, SunTrust Robinson Humphrey, BBVA, DNB Markets, Scotiabank, TD Securities, Academy Securities, AmeriVet Securities, Blaylock Van, LLC, Cabrera Capital Markets, LLC, R. Seelaus & Co. LLC, Ramirez & Co., Inc., Siebert Williams Shank, Tigress Financial Partners · In the order on the cover
- Shares delivered
- On or about Jun 18, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 13, 2020 |
| Filed publicly | May 22, 2020 |
| Amended 3 times | Newest Jun 11, 2020 |
| Shares registered with an exchange | Jun 15, 2020 |
| Declared effective by the SEC | Jun 15, 2020 |
| Final prospectus, with the price | Jun 17, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 17, 2020 |
| EFFECT · Notice that a registration is effective | Jun 15, 2020 |
| S-1MEF · Registration of more shares for the same offering | Jun 15, 2020 |
| CERT · Exchange's certificate of listing | Jun 15, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 15, 2020 |
| CORRESP · Letter to the SEC | Jun 11, 2020 |
| CORRESP · Letter to the SEC | Jun 11, 2020 |
| CORRESP · Letter to the SEC | Jun 11, 2020 |
| S-1/A · Registration statement, amended | Jun 11, 2020 |
| UPLOAD · Letter from the SEC | Jun 9, 2020 |
All 24 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Jun 8, 2020 |
| S-1/A · Registration statement, amended | Jun 2, 2020 |
| S-1 · Registration statement | May 22, 2020 |
| DRS/A · Draft registration statement, amended | May 19, 2020 |
| DRS/A · Draft registration statement, amended | May 18, 2020 |
| DRSLTR · Letter to the SEC with a draft | May 15, 2020 |
| UPLOAD · Letter from the SEC | May 8, 2020 |
| DRS/A · Draft registration statement, amended | Apr 23, 2020 |
| DRSLTR · Letter to the SEC with a draft | Apr 22, 2020 |
| UPLOAD · Letter from the SEC | Apr 13, 2020 |
| DRS/A · Draft registration statement, amended | Mar 27, 2020 |
| DRSLTR · Letter to the SEC with a draft | Mar 26, 2020 |
| UPLOAD · Letter from the SEC | Mar 12, 2020 |
| DRS · Draft registration statement | Feb 13, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 17, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.38B | 2.26B | 2.35B | 2.24B | 2.29B | 2.12B | 1.81B | 1.79B | 1.60B | 1.88B |
| Cost of revenue | 3.85M | 732.5M | 560.7M | 904.2M | 452.8M | 230.8M | 1.02B | 136.0M | 33.3M | 0 |
| Gross profit | 2.38B | 2.26B | 2.35B | 2.24B | 2.29B | 2.12B | 1.81B | 1.79B | 1.60B | 1.88B |
| Research and development | 452.0M | 2.00M | 52.0M | 177.1M | 200.1M | 26.3M | 83.0M | 392.6M | 117.9M | 91.0M |
| Selling, general and administrative | 573.5M | 236.7M | 249.7M | 227.3M | 182.8M | 181.7M | 103.4M | 61.9M | 106.4M | 17.3M |
| Operating income | 1.56B | 1.29B | 1.49B | 307.1M | 1.43B | 1.60B | 2.62B | 1.36B | 939.7M | 722.9M |
| Depreciation and amortization | 3.85M | 0 | 0 | 5.67M | 23.0M | 23.1M | 23.9M | 33.3M | 33.3M | 5.00K |
| EBITDA | 1.56B | 1.29B | 1.49B | 312.7M | 1.45B | 1.62B | 2.65B | 1.40B | 973.0M | 722.9M |
| Interest expense | 307.7M | 225.5M | 187.2M | 188.0M | 166.1M | 157.1M | 268.6M | 280.0M | 247.3M | 238.9M |
| Income before tax | 1.32B | 1.33B | 1.70B | 230.1M | 1.24B | 1.70B | 2.46B | 1.52B | 1.34B | 761.9M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 542.7M | 196.0M |
| Net income | 770.9M | 859.0M | 1.13B | 42.8M | 619.7M | 975.0M | 2.35B | 1.38B | 1.21B | 565.9M |
| Earnings per share, basic | 1.79 | 1.92 | 2.54 | 0.10 | 1.49 | 1.32 | 6.63 | 3.89 | 3.42 | 0.93 |
| Earnings per share, diluted | 1.78 | 1.91 | 2.53 | 0.10 | 1.49 | 1.32 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 618.7M | 929.0M | 477.0M | 1.71B | 1.54B | 1.01B | 246.2M | 1.92B | 1.38B | 1.67B |
| Short-term investments | 18.8M | 58.2M | 18.3M | 1.30M | 66.0M | 70.0M | 0 | 461.8M | ||
| Receivables | 883.7M | 27.0M | 22.4M | 36.6M | 68.3M | 39.2M | 38.8M | 198.6M | ||
| Inventory | 1 | 1 | 657.1M | 19.2M | ||||||
| Current assets | 1.53B | 1.80B | 1.27B | 2.55B | 2.88B | 2.70B | 832.1M | 2.61B | 2.95B | 3.00B |
| Property, plant and equipment | 3.00K | |||||||||
| Goodwill | 924.6M | 0 | ||||||||
| Total assets | 19.6B | 18.2B | 16.4B | 16.8B | 17.5B | 16.0B | 12.4B | 11.4B | 11.4B | 10.5B |
| Accounts payable | 19.4M | 13.4M | 15.2M | 7.91M | 5.62M | 10.8M | 11.2M | 4.48M | 1.88M | |
| Current liabilities | 636.2M | 1.25B | 161.4M | 1.17B | 171.3M | 307.9M | 333.4M | 580.2M | 383.4M | 297.3M |
| Long-term debt | 8.57B | 6.61B | 6.14B | 6.12B | 7.10B | 5.82B | 5.96B | 6.24B | ||
| Total debt | 8.95B | 7.61B | 6.14B | 7.12B | 7.10B | 5.82B | 6.24B | 6.52B | 6.80B | 5.90B |
| Total liabilities | 9.91B | 7.88B | 6.30B | 7.29B | 7.27B | 6.12B | 6.31B | 6.82B | 6.90B | 6.02B |
| Shareholders' equity | 9.71B | 10.3B | 10.1B | 9.53B | 10.2B | 9.90B | 6.14B | 4.55B | 4.46B | 4.45B |
| Shares outstanding | 559.6M | 594.0M | 602.9M | 564.9M | 414.8M | 375.5M | 354.2M | 354.2M | 354.2M | 607.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 2.49B | 2.77B | 2.99B | 2.14B | 2.02B | 2.03B | 1.67B | 1.62B | 1.42B | -15.6M |
| Capital spending | 0 | 0 | -2.12B | -2.04B | -523.0K | -2.20B | -1.72B | -269.6M | -2.29B | 0 |
| Free cash flow | 2.49B | 2.77B | 2.99B | 4.19B | 2.02B | 4.23B | 1.67B | 1.62B | 1.42B | -15.6M |
| Cash from investing | -1.61B | -2.68B | -2.07B | -1.03B | -1.87B | -2.76B | -2.15B | 303.4M | -1.59B | |
| Cash from financing | -1.19B | 361.1M | -2.15B | -944.9M | 385.1M | 1.49B | -1.19B | -1.38B | -123.3M | 2.88M |
| Dividends paid | -378.3M | -376.5M | -358.3M | -333.3M | -285.2M | -397.0M | -739.3M | -814.4M | -735.2M | |
| Share buybacks | -1.23B | -229.7M | -304.8M | 0 | 0 | 0 | -4.27M | 0 | 2.88M | |
| Change in cash | -310.3M | 452.0M | -1.23B | 169.7M | 532.4M | 762.5M | -1.68B | 542.6M | -292.6M | -12.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| 13F-NT | Nov 13, 2026 | Fund holdings report | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 28, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 13F-NT | Aug 14, 2026 | Fund holdings report | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 23, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 4, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 8-K · Current report | May 28, 2026 | Material contract | SEC |
| 144 · Notice of proposed sale | May 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 14, 2026 | Other filings | SEC |
| 13F-NT | May 14, 2026 | Fund holdings report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 28, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 13, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 10, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 10, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 10, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2026 | Other filings | SEC |
| 13F-NT | Apr 1, 2026 | Fund holdings report | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 20, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 11, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 11, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 22, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 22, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 16, 2025 | Material contract | SEC |
| 424B2 · Prospectus | Sep 3, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Sep 2, 2025 | Offer document | SEC |
| 424B2 · Prospectus | Sep 2, 2025 | Offer document | SEC |
| POSASR | Sep 2, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 13, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 11, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 25, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 17, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | May 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 8-K · Current report | May 19, 2025 | Acquisition or disposal | SEC |
| S-8 · Registration statement for employee plans | May 16, 2025 | Offer document | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 8-K · Current report | May 12, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 2, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
This page holds 200 of 647 filings. Open Filings
Cap table
Built by 6ix from Royalty Pharma plc’s releases · as of Sep 2, 2025
- Common shares
- 445,265,805
- Fully diluted
- 445,265,805
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 445,265,805 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 445,265,805 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ted W Love Other companies: Lisata Therapeutics, Inc. (Director · Since at least Sep 17, 2026); Jazz Pharmaceuticals plc (Director · Since at least Dec 1, 2025); Gilead Sciences, Inc. (Director · Since at least Feb 1, 2024); Structure Therapeutics, Inc. (Director · Since at least Aug 3, 2023); Seagen Inc (Director · Aug 16, 2020 – Dec 14, 2023 · Past); Portola Pharmaceuticals Inc (Director · Sep 18, 2019 – Jul 2, 2020 · Past); Global Blood Therapeutics Inc (President and CEO, Director · Aug 11, 2015 – Oct 5, 2022 · Past); Cascadian Therapeutics Inc (Director · Sep 5, 2013 – Mar 9, 2018 · Past); Savara, Inc. (Director · Sep 5, 2012 – Jun 19, 2013 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); Amicus Therapeutics Inc (Director · Jun 13, 2012 – Jun 4, 2020 · Past); Bio-Rad Laboratories, Inc. (Director · Mar 24, 2010 – Mar 24, 2010 · Past); Onyx Pharmaceuticals Inc (EVP, R&D and Tech. Operations · Feb 1, 2010 – Jul 25, 2012 · Past); Affymax Inc (Director · Dec 14, 2006 – Jun 13, 2012 · Past); Santarus Inc (Director · Jun 7, 2006 – Jan 2, 2014 · Past); Oruka Therapeutics, Inc. (Director · Mar 7, 2006 – Feb 5, 2010 · Past) | Director · Since at least Jul 30, 2020 |
| Vlad Coric Other companies: Veradermics, Incorporated (Board Member · Since at least Feb 3, 2026); Biohaven Ltd. (Chairman & Chief Executive Officer · Since at least Sep 22, 2022); Revance Therapeutics, Inc. (Director · Mar 1, 2023 – Feb 4, 2025 · Past); Akili Inc (Director · Jun 29, 2021 – Jun 29, 2021 · Past); Biohaven Pharmaceutical Holding Co Ltd (Chief Executive Officer, Director · May 3, 2017 – Oct 3, 2022 · Past) | Director · Since at least Apr 7, 2025 |
| Carole Ho Other companies: Eli Lilly and Company (Executive Vice President and President, Lilly Neuroscience · Since at least Dec 31, 2025); Beam Therapeutics Inc. (Director · Since at least Feb 5, 2020); Denali Therapeutics Inc. (Chief Medical Officer · Since at least Apr 1, 2019); NGM Biopharmaceuticals Inc (Director · Jun 5, 2020 – Apr 5, 2024 · Past) | Director · Since at least Jul 17, 2025 |
| Elizabeth Weatherman Other companies: Insulet Corporation (Director · Since at least May 22, 2024); Silk Road Medical Inc (Director · Jun 18, 2024 – Sep 17, 2024 · Past); Vapotherm Inc (Director · Jan 1, 2024 – Sep 20, 2024 · Past); Nevro Corp (Director · Sep 30, 2023 – Apr 3, 2025 · Past) | Director · Since at least Jul 17, 2025 |
| Gregory Norden Other companies: Praxis Precision Medicines, Inc. (Director · Since at least Oct 15, 2020); Zoetis Inc. (Director · Since at least Feb 11, 2020); Entasis Therapeutics Holdings Inc (Director · Jun 19, 2019 – Jun 19, 2019 · Past); NanoString Technologies Inc (Director · Jun 18, 2019 – May 6, 2024 · Past) | Director · Since at least Jun 15, 2020 |
| Bonnie Bassler Other companies: Cidara Therapeutics Inc (Director · Since at least Jan 22, 2021); Regeneron Pharmaceuticals, Inc. (Chair, Department of Molecular Biology, and Squibb Professor in Molecular Biology, Princeton University · Since at least Sep 9, 2016); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Jun 30, 2021 · Past) | Board Member · Since at least Jun 15, 2020 |
| Christopher Hite Other companies: Kailera Therapeutics, Inc. (Independent Board Member · Since at least Apr 16, 2026); Vera Therapeutics, Inc. (EVP and Vice Chairman, Royalty Pharma · Since at least Mar 5, 2026); Acceleron Pharma Inc (Director · Jun 4, 2020 – Nov 19, 2021 · Past) | EVP & Chairman, Partnering · Since at least Jun 15, 2020 |
| Rory Riggs Other companies: Cibus, Inc. (Director · Since at least May 31, 2023); Kyntra Bio, Inc. (Director · Nov 13, 2014 – May 26, 2021 · Past); Intra-Cellular Therapies Inc (Director · Jan 8, 2014 – Apr 2, 2025 · Past) | Director · Jun 15, 2020 – Feb 20, 2024 · Past |
| David C. Hodgson Other companies: Alignment Healthcare, Inc. (Director · Since at least Mar 26, 2021); TriNet Group, Inc. (Director · Since at least Mar 21, 2014) | Vice Chairman · Since at least Jun 23, 2022 |
| Errol B Desouza Other companies: Alector, Inc. (Director · Since at least Mar 19, 2024); Cyclerion Therapeutics, Inc. (Director · Nov 30, 2023 – Nov 30, 2023 · Past) | Director · Jun 7, 2024 – May 13, 2025 · Past |
All 29 people
| Person | Seat |
|---|---|
| Pablo Legorreta Other companies: ProKidney Corp. (Chairman of the Board · Since at least Jul 11, 2022); Epizyme Inc (Director · Nov 6, 2019 – Aug 12, 2022 · Past) | Founder & Chief Executive Officer · Since at least Jun 15, 2020 |
| Ted W. Love Other companies: Gilead Sciences, Inc. (Director · Since at least May 4, 2026); Jazz Pharmaceuticals plc (Director, Jazz Pharmaceuticals plc · Since at least Nov 5, 2025) | Board Member · Since at least Sep 29, 2025 |
| William E Ford Other companies: BlackRock, Inc. (Director · Since at least Sep 30, 2020); Ihs Markit Ltd (Director · Dec 15, 2020 – Feb 28, 2022 · Past) | Director · Oct 20, 2020 – Jun 30, 2021 · Past |
| Catherine M Engelbert Other companies: McDonald's Corporation (Director · Since at least Dec 31, 2023) | Director · Since at least Jun 7, 2024 |
| Greg Norden Other companies: Praxis Precision Medicines, Inc. (Director · Since at least Jun 12, 2026) | Board Member · Since at least Jun 8, 2026 |
| Henry A. Fernandez Other companies: MSCI Inc. (Chairman and CEO, Director · Since at least Feb 8, 2023) | Director · Since at least Mar 31, 2022 |
| Arthur McGivern | General Counsel & Investments · Since at least Jan 1, 2026 |
| Cathy Engelbert | Board Member · Since at least Jun 8, 2026 |
| Eric Schneider | Chief Technology Officer · Since at least Nov 4, 2026 |
| Greg Raskin | Head of Academic Initiatives · Since at least Aug 3, 2026 |
| James F Reddoch | EVP & Chief Scientific Officer · May 19, 2022 – Sep 28, 2022 · Past |
| Jim Reddoch | Chief Scientific Officer & Investments · Since at least Nov 4, 2026 |
| Kenneth Sun | Head of Asia · Since at least Mar 3, 2026 |
| Lucas Glass | Head of Artificial Intelligence · Since at least Mar 23, 2026 |
| Mario Germano Giuliani | Director · Jun 15, 2020 – Jun 23, 2023 · Past |
| Marshall Urist | Head of Research & Investments · Since at least Aug 12, 2024 |
| Nick Montemarano | Executive Director, Investor Relations · Since at least Mar 27, 2026 |
| Scott Raichilson | Chief Accounting Officer · Since at least Nov 5, 2026 |
| Terrance Coyne | Chief Financial Officer · Since at least Aug 12, 2024 |
Log in to ask 6ix AI your own questions about Royalty Pharma plc.